New hope for AML patients: maintenance drug may delay relapse

NCT ID NCT04990102

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Mar 29, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This study tests a chemotherapy drug called CPX-351 as a maintenance treatment for adults with acute myeloid leukemia (AML) who are in remission but cannot have a bone marrow transplant. The goal is to find a safe dose and see if it helps keep the cancer from coming back. About 24 participants will receive up to 6 cycles of the drug, and researchers will monitor side effects and survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) IN REMISSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Georgetown Lombardi Comprehensive Cancer Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA (AML) IN REMISSION